Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment‐refractory triple‐negative breast cancer (TNBC), where those with Programmed death‐ligand 1 (PD‐L1) positive early‐stage disease had improved responses. ICIs are administered systemically in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hsuan‐Chen, Capuani, Simone, Badachhape, Andrew A., Di Trani, Nicola, Davila Gonzalez, Daniel, Vander Pol, Robin S., Viswanath, Dixita I., Saunders, Shani, Hernandez, Nathanael, Ghaghada, Ketan B., Chen, Shu‐Hsia, Nance, Elizabeth, Annapragada, Ananth V., Chua, Corrine Ying Xuan, Grattoni, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658527/
https://www.ncbi.nlm.nih.gov/pubmed/38023719
http://dx.doi.org/10.1002/btm2.10594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658527/
https://www.ncbi.nlm.nih.gov/pubmed/38023719
http://dx.doi.org/10.1002/btm2.10594

Ejemplares similares